| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies
|
Harb, Wael
|
|
|
21 |
12 |
p. 823-830
|
article
|
| 2 |
Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience
|
Riva, Marcello
|
|
|
21 |
12 |
p. e970-e974
|
article
|
| 3 |
Editorial Board
|
|
|
|
21 |
12 |
p. A4-A5
|
article
|
| 4 |
IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era
|
Buege, Michael J.
|
|
|
21 |
12 |
p. 873-878
|
article
|
| 5 |
Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience
|
la Torre, Alfredo De
|
|
|
21 |
12 |
p. e946-e959
|
article
|
| 6 |
Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation
|
Li, Yanfen
|
|
|
21 |
12 |
p. 841-851
|
article
|
| 7 |
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
|
Chari, Ajai
|
|
|
21 |
12 |
p. e975-e984
|
article
|
| 8 |
Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation
|
Kedmi, Meirav
|
|
|
21 |
12 |
p. e929-e937
|
article
|
| 9 |
Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia
|
Bazarbachi, Abdul Hamid
|
|
|
21 |
12 |
p. 831-840
|
article
|
| 10 |
Primary Cutaneous B-Cell Lymphomas in Children and Adolescents: A SEER Population-Based Study
|
Bomze, David
|
|
|
21 |
12 |
p. e1000-e1005
|
article
|
| 11 |
Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients
|
Elrhman, Heba Allah E Abd
|
|
|
21 |
12 |
p. e960-e969
|
article
|
| 12 |
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
|
Abrisqueta, Pau
|
|
|
21 |
12 |
p. e985-e999
|
article
|
| 13 |
Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience
|
Ghafouri, Sanaz
|
|
|
21 |
12 |
p. 861-872
|
article
|
| 14 |
Repertoire of Rearranged Immunoglobulin Heavy Chain Genes in Russian Patients With B-Cell Lymphoproliferative Diseasesā°
|
Biderman, Bella V.
|
|
|
21 |
12 |
p. e938-e945
|
article
|
| 15 |
SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML
|
Inguva, Anagha
|
|
|
21 |
12 |
p. 805-811
|
article
|
| 16 |
Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma
|
George, Laeth L.
|
|
|
21 |
12 |
p. 812-822
|
article
|
| 17 |
Table of Contents
|
|
|
|
21 |
12 |
p. A9-A10
|
article
|
| 18 |
The Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients With Acute Myeloid Leukemia: A 10-Year Experience
|
Rungjirajittranon, Tarinee
|
|
|
21 |
12 |
p. 852-860
|
article
|
Journal description